La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Betta Pharmaceuticals Salute del bilancio

Salute finanziaria criteri di controllo 3/6

Betta Pharmaceuticals ha un patrimonio netto totale di CN¥5.6B e un debito totale di CN¥2.3B, che porta il suo rapporto debito/patrimonio netto a 42.1%. Le sue attività totali e le sue passività totali sono rispettivamente CN¥9.1B e CN¥3.6B. L'EBIT di Betta Pharmaceuticals è CN¥431.4M rendendo il suo rapporto di copertura degli interessi 11.3. Ha liquidità e investimenti a breve termine pari a CN¥465.4M.

Informazioni chiave

42.1%

Rapporto debito/patrimonio netto

CN¥2.34b

Debito

Indice di copertura degli interessi	11.3x
Contanti	CN¥465.45m
Patrimonio netto	CN¥5.56b
Totale passività	CN¥3.58b
Totale attività	CN¥9.14b

Aggiornamenti recenti sulla salute finanziaria

These 4 Measures Indicate That Betta Pharmaceuticals (SZSE:300558) Is Using Debt Reasonably Well

Jul 05

Recent updates

Betta Pharmaceuticals Co., Ltd.'s (SZSE:300558) P/E Is Still On The Mark Following 29% Share Price Bounce

Sep 30

Results: Betta Pharmaceuticals Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates

Aug 07

Unpleasant Surprises Could Be In Store For Betta Pharmaceuticals Co., Ltd.'s (SZSE:300558) Shares

Jul 30

These 4 Measures Indicate That Betta Pharmaceuticals (SZSE:300558) Is Using Debt Reasonably Well

Jul 05

Betta Pharmaceuticals' (SZSE:300558) Earnings Are Weaker Than They Seem

Apr 26

Earnings Miss: Betta Pharmaceuticals Co., Ltd. Missed EPS By 6.1% And Analysts Are Revising Their Forecasts

Apr 23

What Betta Pharmaceuticals Co., Ltd.'s (SZSE:300558) P/E Is Not Telling You

Apr 16

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( { 300558 di CN¥1.2B ) non coprono le sue passività a breve termine ( CN¥1.7B ).

Passività a lungo termine: Le attività a breve termine di 300558 ( CN¥1.2B ) non coprono le sue passività a lungo termine ( CN¥1.9B ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: Il rapporto debito netto/patrimonio netto ( 33.8% ) di 300558 è considerato soddisfacente.

Riduzione del debito: Il rapporto debito/patrimonio netto di 300558 è aumentato da 30.2% a 42.1% negli ultimi 5 anni.

Copertura del debito: Il debito di 300558 è ben coperto dal flusso di cassa operativo ( 45.9% ).

Copertura degli interessi: I pagamenti degli interessi sul debito di 300558 sono ben coperti dall'EBIT ( 11.3 x copertura).

Betta Pharmaceuticals Salute del bilancio

Salute finanziaria criteri di controllo 3/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

These 4 Measures Indicate That Betta Pharmaceuticals (SZSE:300558) Is Using Debt Reasonably Well

Recent updates

Betta Pharmaceuticals Co., Ltd.'s (SZSE:300558) P/E Is Still On The Mark Following 29% Share Price Bounce

Betta Pharmaceuticals Co., Ltd. to Report Q3, 2024 Results on Oct 29, 2024

Investor sentiment improves as stock rises 33%

New minor risk - Share price stability

Consensus EPS estimates increase by 15%, revenue downgraded

Results: Betta Pharmaceuticals Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates

New minor risk - Earnings quality

Second quarter 2024 earnings: EPS exceeds analyst expectations

Unpleasant Surprises Could Be In Store For Betta Pharmaceuticals Co., Ltd.'s (SZSE:300558) Shares

These 4 Measures Indicate That Betta Pharmaceuticals (SZSE:300558) Is Using Debt Reasonably Well

Betta Pharmaceuticals Co., Ltd. to Report First Half, 2024 Results on Aug 06, 2024

Dividend increased to CN¥0.17

Betta Pharmaceuticals Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares as Cash Dividend (Tax Included) for the Year 2023, Payable on 06 June 2024

Consensus EPS estimates fall by 17%

Price target decreased by 9.5% to CN¥51.64

Betta Pharmaceuticals' (SZSE:300558) Earnings Are Weaker Than They Seem

Consensus EPS estimates increase by 20%, revenue downgraded

Earnings Miss: Betta Pharmaceuticals Co., Ltd. Missed EPS By 6.1% And Analysts Are Revising Their Forecasts

Price target increased by 12% to CN¥65.00

Betta Pharmaceuticals Co., Ltd., Annual General Meeting, May 15, 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

What Betta Pharmaceuticals Co., Ltd.'s (SZSE:300558) P/E Is Not Telling You

Betta Pharmaceuticals Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Investor sentiment improves as stock rises 16%

Investor sentiment improves as stock rises 18%

Betta Pharmaceuticals Co., Ltd. to Report Fiscal Year 2023 Results on Apr 20, 2024

Consensus EPS estimates increase by 12%, revenue downgraded

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Betta Pharmaceuticals Co., Ltd. to Report Q3, 2023 Results on Oct 25, 2023

Consensus EPS estimates fall by 13%

Price target decreased by 16% to CN¥57.04

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Share price stability

Betta Pharmaceuticals Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2022, Payable on 15 June 2023

Betta Pharmaceuticals Co., Ltd. Approves Cash Dividend for the Year of 2022

Price target increased by 13% to CN¥50.59

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Betta Pharmaceuticals Co., Ltd. Approves Board Elections

Insufficient new directors

Consensus revenue estimates fall by 14%

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 11%

Price target decreased to CN¥57.39

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Betta Pharmaceuticals Co., Ltd. announced that it expects to receive CNY 999.999991 million in funding

Investor sentiment improved over the past week

Betta Pharmaceuticals Co., Ltd. Announces Cash Dividend for 2021, Payable on 30 May 2022

High number of new and inexperienced directors

Betta Pharmaceuticals Co., Ltd., Annual General Meeting, Apr 28, 2022

Betta Pharmaceuticals Co., Ltd. Proposes Final Cash Dividend for 2021

Full year 2021 earnings: EPS and revenues miss analyst expectations

Consensus forecasts updated

Price target decreased to CN¥117

Third quarter 2021 earnings released: EPS CN¥0.32 (vs CN¥0.92 in 3Q 2020)

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.16 (vs CN¥0.033 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.36 (vs CN¥0.33 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥1.50 (vs CN¥0.58 in FY 2019)

New 90-day low: CN¥95.46

Investor sentiment deteriorated over the past week

Betta Pharmaceuticals Co., Ltd. to Report Fiscal Year 2020 Results on Mar 26, 2021

Analysts update estimates

Price target raised to CN¥97.57

New 90-day high: CN¥120

Market pulls back on stock over the past week

New 90-day low: CN¥99.80

Analysts update estimates

Third-quarter earnings released: Revenue and earnings beat expectations

Third quarter earnings released

New 90-day low: CN¥108

Analysts update estimates

New 90-day low - CN¥110

Ningbo Kaiming Innovation Technology Co., Ltd. completed the acquisition of Zhejiang Betta Pharmaceutical Technology Co., Ltd. from Betta Pharmaceuticals Co., Ltd. (SZSE:300558).

Earnings released